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amide (Fig. 1), is a synthetic antibiotic belonging to
a new class of antimicrobials called the oxazolidi-
nones (3).
In vitro microbiological studies showed that
linezolid is effective against various antibiotic-
resistant isolates of staphylococci, streptococci,
enterococci, and pneumococci (4). Linezolid
exhibits a unique mechanism of inhibition of bacte-
rial protein synthesis at the initiation phase of trans-
lation (5). 
The pharmacokinetics and pharmacodynamics
of linezolid have been extensively investigated in
healthy volunteers and patients (6-10). There are
two major metabolites of linezolid (PNU-142586
and PNU-142300). Linezolid and its two main
metabolites plus several minor ones are all excreted
in the urine (6). 
Increased knowledge of the pharmacokinet-
ic/pharmacodynamic properties of antibiotics is use-
ful for optimizing dosage. Linezolid is a time-
dependent antimicrobial agent with persistent post-
antibiotic effect. The pharmacokinetics/pharmaco-
dynamics parameters best suitable to define its
activity are time with serum concentrations higher
than the minimum inhibitory concentration (TC>MIC)
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Abstract: A high-performance liquid chromatographic (HPLC) method with UV and DAD detection for the
quantitative determination of linezolid in human serum was developed in present work. Chromatography was
carried out by reversed-phase technique on a RP-18 column with a mobile phase composed of 50 mM phos-
phate buffer and acetonitrile (76 : 26, v/v), adjusted to pH 3.5 with orthophosphoric acid. Serum samples were
deproteinized with methanol centrifuged and then, the supernatant was analyzed using HPLC procedure. No
interference was observed at the retention times of linezolid from blank serum or ten commonly used antibi-
otics. A concentration range from 0.50 to 30.0  g/mL was utilized to construct calibration curves. The lower
limit of detection was determined to be 0.1 µg/mL of serum for both detectors. The lower limit of quantifica-
tion of 0.25 µg/mL (CV = 2.6%) was established for determination using HPLC-UV and 0.5 µg/mL (CV =
5.42%) for HPLC-DAD. The recovery of linezolid was approximately 100%. Intra-day accuracy ranged from
0.97 to 12.63% and 0.74 to 10.85% for HPLC-UV and HPLC-DAD method, respectively. Intra-day precision
was less than 4.69% for HPLC-UV and less than 5.42% for HPLC-DAD method. Tests confirmed the stabili-
ty of linezolid in serum during three freeze-thaw cycles and during long-term storage of frozen serum for up to
6 weeks; in extracts it was stable in the HPLC autosampler over 24 h. Statistical analysis by Student's t-test
showed no significant difference between the results obtained by these two methods. In summary, these meth-
ods will be used and adapted for infected patients in intensive care unit, to determine linezolid serum concen-
trations in order to know the pharmacokinetic profiles of linezolid. 
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Figure 1. Chemical structure of linezolid (3)
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and area under the serum concentration-time curve/
minimum inhibitory concentration (AUC/MIC)
ratio. Data suggest that percentage time above the
MIC (%TC>MIC) above 85 and AUC/MIC ratio above
100 are good predictors of the development of
resistance to linezolid. The pharmacokinetic param-
eters are highly variable between individuals so that
determination of linezolid serum concentrations is
necessary to ensure the treatment effectiveness.
Inter-patient differences in pharmacokinetics and
the frequently associated toxicity of linezolid after
prolonged use makes therapeutic drug monitoring
(TDM) strongly recommended. Therefore, a good
analytical method for linezolid in human fluids is
necessary (6, 11). 
Several determinations of linezolid in human
fluids using a high-performance liquid chromato-
graphic method coupled with ultraviolet detection
(HPLC/UV) have been published (12-19). Some of
them described a manual solid-phase extraction (12,
13) or protein precipitation for sample clean-up (14-
19). The solid-phase extraction is an expensive
method which often involves multi-step purification
and evaporation, and a plasma/serum volume of at
least 0.5 to 1 mL is usually required. The advantages
of protein precipitation over solid-phase extraction
are good extraction recovery values (close to 100%)
as well as simple and less-time consuming proce-
dure. 
High-performance liquid chromatographic
method coupled with diode array detection
(HPLC/DAD) is a commonly used method in labo-
ratories nowadays for the analysis of many different
drugs, metabolites and compounds (20-24).
However, there are a few HPLC/DAD methods for
measuring linezolid in human fluids (25, 26). In our
paper we would like to show that HPLC/DAD
method can also be used for routine determination of
linezolid in human serum in clinical applications. 
The objective of this study was to compare
HPLC/UV method with HPLC method coupled with
diode array detection. HPLC/DAD is a method less
commonly used for pharmacokinetic and pharmaco-
dynamic studies in humans and animals. The aim of
the study was also to develop a simple, rapid and
low-cost method for estimation of linezolid in
human serum, without solid phase extraction, using
HPLC method coupled with ultraviolet detection
and to validate the method according to the US Food
and Drug Administration (FDA) (1, 2). This method
will be used and adapted for patients in intensive
care unit (ICU) to determine the linezolid serum
concentrations in order to analyze the pharmacoki-
netic profiles of linezolid in ICU infected patients. 
EXPERIMENTAL
Chemicals and reagents
Linezolid was supplied by Pharmacia
Corporation (Switzerland). Other antibiotics used
included: amoxicillin, imipenem, meropenem, cef-
tazidime, cefuroxime, cefepime, cefoperazone, cef-
tazidime, ciprofloxacin, piperacillin (Sigma-
Aldrich, Germany) and vancomycin (Merck,
Germany). Acetonitrile and methanol for chro-
matography LiChrosolv® were obtained from Merck
(Darmstadt, Germany) and analytical grade, concen-
trated orthophosphoric acid (85%) and potassium
dihydrogen phosphate were purchased from Fluka
(Germany). Drug free human serum was received
from the healthy volunteer.
Apparatus and chromatographic conditions
The HPLC/UV system  (Thermo Separation
Products, San Jose, CA, USA) consisted of a P100
pump, a Rheodyne injector 7125 (Rheodyne, Cotati,
CA, USA) with a 50 µL loop, a UV100 variable-
wavelenghth UV/VIS detector, and a SP4400
(ChromJet) integrator. 
The HPLC/DAD system (HITACHI LaChrom
Elite) consisted of a HITACHI L-2130 pump, a
HITACHI L-2350 column oven and a HITACHI L-
2200 autosampler. The detector used was a
HITACHI L-2455 DAD detector, which was set to
scan from 190 to 800 nm. Peak areas were integrat-
ed automatically using the EZChrom Elite
Client/Server version 3.2 (Scientific Software Inc.
Agilent 2005-2006) workstation.
The analytical column was a LiChrospher®
100RP-18 (250 ◊ 4 mm i.d., 5 µm particle size) from
Merck (Darmstadt, Germany) coupled with a
LiChroCART guard column (5 µm, 4.0 ◊ 4.0 mm,
Merck).
The mobile phase consisted of a mixture of
acetonitrile ñ 50 mM potassium dihydrogen phos-
phate buffer (26 : 74, v/v). It was prepared with
6.8040 g potassium dihydrogen phosphate dis-
solved in 1000 mL of water. The pH was adjusted
to 3.5 with concentrated orthophosphoric acid. The
mobile phase was prepared daily, filtered through a
0.45 µm membrane filter (Supelco, Germany) and
degassed before use. Linezolid was eluted isocrati-
cally with a flow rate of 1.0 mL/min. The peak of
linezolid was detected by UV and DAD detection,
the  wavelength was monitored at 258 nm. The
sample injection volume was 50 µL. The chromato-
graphic run time was 9 min. The HPLC system was
operated at 22 ± 1OC.
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Preparation of solutions
A stock solution of linezolid (1 mg/mL) was
prepared by dissolving linezolid standard in deion-
ized water. The stock standard solution was diluted
with water to obtain working solutions of 0.5; 2.5;
5.0; 10.0; 20.0 and 30.0 µg/mL for serum calibration
samples. 
Quality controls (QC) samples were prepared
by adding an appropriate volume of the stock solu-
tions to drug free serum to obtain a final concentra-
tion of 0.5, 1.0, 7.5 and 15.0 µg/mL (respectively
LOQ, low, medium and high QC). 
The stock and working standard solutions were
stored in a refrigerator (4OC) when not in use. 
Sample preparation
Eppendorf tube was added of linezolid (25 µL),
followed by serum (225 µL). Mixture was vortex-
mixted for 10 s and the tube was added of methanol
(500 µL). The solution was vortexed for 30 s and
centrifuged for 10 min at 15000 rpm at room tem-
perature. Finally, 50 µL of the clear supernatant of
each sample was injected into HPLC apparatus.
Patients' blood samples were centrifuged at
1000 ◊ g for 10 min, not later than 20 min after col-
lection. On the day of analysis, after thawing, 250
µL of samples were vortex-mixted for 10 s. Then,
serum samples were deproteinized with methanol
(500 µL) and the solution was vortexed for 30 s and
centrifuged for 10 min at 15 000 rpm at room tem-
perature. Finally, 50 µL of the clear supernatant of
each sample was injected into HPLC apparatus. All
samples were prepared in duplicate. 
VALIDATION
Validation procedures, parameters and accept-
ance criteria were based on FDA and recommenda-
tions in the literature (1, 2). The method was then
validated regarding selectivity and specificity, lin-
earity, accuracy and precision, limit of detection and
limit of quantitation, recovery and stability.
Selectivity and specificity
The selectivity was evaluated by the analysis of
samples drug-free serum applying the analytical pro-
cedure, the retention times of endogenous compounds
were compared with that obtained for linezolid.
Specificity of the method was evaluated by
injecting solutions containing other anti-infective
drugs largely used in broad spectrum antibiotic
treatment: amoxycillin, imipenem, meropenem, cef-
tazidime, cefuroxime, cefepime, cefoperazone, cef-
tazidime, ciprofloxacin, and piperacillin. 
Linearity
Linearity study was performed by analysis of
standards in sixplicate on 5 days between 0.5 and
30.0 µg/mL. Calibration curves of linezolid was
established using peak area analyte (y) versus serum
concentration (x). Slopes, intercepts and correlation
coefficients (r) were obtained by linear regression
analysis. 
Accuracy and precision
Inter-day study was performed by assaying the
six QC concentrations once-a-day on 7 separate
days. Mean measured concentrations and their stan-
dard deviations (S.D.) were calculated. Precision
was reported by calculating the coefficient of varia-
tion (CV) expressed as (S.D./mean) ◊ 100 and accu-
racy by the bias expressed as [(measured concentra-
tion - theoretical concentration)/(theoretical concen-
tration)] ◊ 100. Acceptance criteria for accuracy and
precision were: bias within ±15% (except ± 20% for
Figure 2. Chromatograms of (A) linezolid-free human serum, (B)
serum spiked with 0.5 µg/mL and (C) 20.0 µg/mL of linezolid. (1)
indicates the position of linezolid. HPLC/UV
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the LOQ QC) and CV lower than 15% (except 20%
for the LOQ QC) (1, 2).
Statistical comparison of the results analysis by
the two detection systems (UV and DAD) was per-
formed with regard to accuracy and precision using
Student's t-test at 95% confidence level. 
Limit of detection and limit of quantitation
The limit of detection (LOD) was defined by
the concentration with a signal-to-noise ratio of 3.
The limits of quantification (LOQ) were experimen-
tally determined by analyzing serum samples spiked
with linezolid at 0.25, 0.5, 1.0, 2.0 and 2.5 µg/mL
concentrations. The lower LOQ was chosen as the
concentration which provided measurements with a
precision and accuracy within the recommended 
± 20% from their nominal values, in accordance
with the FDA guidelines (1, 2).
Recovery
Linezolid recoveries were quantified at con-
centration levels corresponding to the lowest (0.5
Figure 3. Chromatograms of (A) linezolid-free human serum, (B) serum spiked with 0.5 µg/mL and (C) 20.0 µg/mL of linezolid. (1) indi-
cates the position of linezolid. HPLC/DAD
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µg/mL) medium (10.0  g/mL) and highest standards
values (30.0 µg/mL) analyzed in sixplicate.
Absolute recovery of linezolid from serum was esti-
mated by the peak area integrated for linezolid in
serum assayed, accordingly the procedure versus the
peak area integrated for linezolid, after direct injec-
tion of the same concentration in purified water;
expressed as percentage.
Linezolid stability 
Stability of linezolid in human serum was
evaluated after short-term, long-term storage, and
through several freeze and thaw cycles. Low (1.0
µg/mL), medium (7.5 µg/mL) and high (15.0
µg/mL) QC concentrations were prepared in tripli-
cate from a freshly made stock solution in human
serum and were investigated under different condi-
tions. Long-term stability was studied by assaying
samples that had been stored at ñ30OC for 44 days.
Short-term stability was assessed at different tem-
peratures (in the HPLC autosampler at 4OC and
room temperature at 22 ± 1OC). QC samples were
analyzed in triplicate after different times of storage
(0, 2, 5, 9 and 24 h). 
All data were compared with results obtained
from freshly prepared and analyzed QC samples
using the formula: stability (%) = (stored QC con-
centration/freshly prepared QC concentration) ◊
100. Linezolid stability was confirmed if less than
10% difference in concentration was observed. 
Linezolid stability was assayed also after one,
two or three freeze-thaw cycles. This was deter-
mined by assay (n = 3) of a serum and water line-
zolid (15.0 µg/mL) samples thawed after storage at
ñ30OC. The samples were returned to the freezer,
frozen, thawed and assayed (n = 3) one more time.
The percentage concentrations of linezolid were cal-
culated after each cycle and compared to freshly
prepared QC samples of linezolid in human serum
and water. The acceptance criterion for serum and
water concentrations studies was adopted as less
than 15% variation.
Application of the method
One patient (K.L.) was a female, 60-year-old
(weight 60 kg, height 165 cm) with respiratory tract
infections hospitalized in the Department of
Anesthesiology and Intensive Care, Specialistic
Hospital in KrakÛw, Poland. Linezolid (ZivoxidÆ)
was administered by 1 h infusion every 24 h at a
dose of 600 mg. Blood samples were taken at the
fourth day of treatment (steady-state) before the next
dose, just after the cessation of the infusion and 4
and 7 h after infusion. Serum linezolid levels were
determined by a previously reported high perform-
ance chromatography method with UV detection. 
Figure 4. Chromatograms: serum control (A), serum of the patient
being treated with linezolid (before infusion) (B), 7 h after the start
of the infusion (C). (1) indicates the position of linezolid
Table 1. Drugs commonly prescribed with the linezolid study of
the specificity of the analytical method by HPLC-UV.
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The study protocol was approved by the




Typical chromatograms for a blank serum, low
(0.5 µg/mL) and high (20.0 µg/mL) concentration of
linezolid in serum are shown in Figures 2 and 3. The
retention time of linezolid was in the range 6.9 ñ 7.2
min and each chromatographic run required approx-
imately 9 min. Figure 4 presents chromatograms
obtained from analysis of (A) a blank serum; (B, C)
a serum obtained from a patient treated with linezol-
id that had been administered intravenously at the
standard dosage (600 mg) every 12 h.
Presented in Figure 4 chromatograms of serum
samples, show, respectively, control and examined
patient (K.L.) treated with linezolid, and confirmed
the good separation of determined compound in the
biological matrix. There was no interference of the
tested antibiotic with the components of biological
background, metabolites and the other drug co-
administered (fraxiparine, metoclopramide,
amizepine, pentoxifylline, acetylcysteine, omepra-
zole, fluconazole) to the patient during hospitaliza-
tion.
Selectivity of the assay
Blank serum showed no interfering endoge-
nous substances in the analysis of linezolid.
Potentially co-administered drugs tested had reten-
tion times that were different from linezolid or were
not extracted and detected.  Retention time of line-
zolid was 6.9 ñ 7.2 min and all other drugs were
eluted without interaction with the signal of linezol-
id (see Tab. 1).
Linearity of the assay
The linearity study was carried out with con-
centrations ranging from 0.5 to 30.0 µg/mL in
serum. Calibration curves exhibited excellent linear-
ity through the coefficient of correlation r = 0.9995
and 0.9997, respectively, for HPLC/UV and
HPLC/DAD determination. Regression intercepts
for the calibration curves were not statistically sig-
nificant compared to zero. Standard curves obtained
from different calibration lines performed on differ-
ent days were y = 103148∑x ñ 47771.6 for
HPLC/UV and y = 206185∑x ñ 7870.8 for
HPLC/DAD determination, where y = peak area and
x = concentration. 
Limit of detection and lower limit of quantifica-
tion 
The lower limit of detection was determined to
be 0.1 µg/mL of serum at a signal-to-noise ratio 3 :
1 for both detectors. The lower limit of quantifica-
tion of 0.25 µg/mL (CV = 2.6%) was established for
determination using HPLC/UV and 0.5 µg/mL (CV
= 5.42%) for HPLC/DAD. These values are suffi-
cient for the determination of therapeutic concentra-
tions of studied drug. Based on the above data it can
be concluded, that the UV detector has a higher sen-
sitivity than the DAD detector.
Recovery of the analyte
Peaks area data of spiked serum samples were
compared to the results of aqueous solutions at the
same nominal concentrations. Recovery of spiked
serum samples approximated to 100%, with average
100.5 ± 4.3% (CV = 4.27%). It shows very high
extraction efficiency.
Accuracy and precision
The precision and the accuracy of the
HPLC/UV and DAD developed methods are given
in Tables 2 and 3. Intra-day accuracy ranged from
0.97 to 12.63% and 0.74 to 10.85% for HPLC/UV
and HPLC/DAD method, respectively. However,
intra-day precision was less than 4.69% for
HPLC/UV and less than 5.42% for HPLC/DAD
method. 
From the results it can be concluded that the
developed method has good precision and excellent
accuracy in the range of tested concentrations.
The Student's t-test was applied between the
experimental values obtained in the sample analysis
by the two methods regarding the accuracy and the
precision. The linezolid levels obtained for 84 blood
samples by HPLC/UV (n = 42) and HPLC/DAD (n
= 42). We found: HPLC/UV (µg/mL) = HPLC/DAD
(µg/mL) ñ 0.0925 (µg/mL) with a correlation coef-
ficient r = 0.998. Figure 5 shows the correlation and
the 95% confidence interval.
The Student's t-test did not reveal significant
difference between the experimental values obtained
in the sample analysis by the two detectors.
Stability
The study was based on determining the con-
centration of linezolid in the pre-prepared samples,
stored at the proper temperature for a certain time
and then determining the percentage of degeneration
of the drug under the influence of temperature.
The stability of linezolid was investigated at
three different conditions: at 22 ± 1OC (room tem-
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perature), at 4OC (room in the HPLC autosampler)
for 24 h and at ñ30OC (for 44 days). The linezolid
levels in serum were measured by HPLC/UV 
and by HPLC/DAD. These results are shown in
Figure 6.
Based on the results, we can conclude that the
drug is stable and does not undergo significant dis-
integration in all studied temperatures. At room
temperature after 24 h, a decrease of the amount of
linezolid in human serum samples was 15% for
lower and 7% for higher concentrations. These data
indicated also that linezolid in human serum sam-
ples was stable for 24 h when stored at the tempera-
ture 4OC (room in the HPLC autosampler). Linezolid
was completely stable in frozen human serum at
ñ30OC for at least 44 days. 
The stability of linezolid in serum and aqueous
samples after one to three freeze-thaw cycles was
evaluated. After each thawing, concentration of the
drug was tested and percentage of degradation of
linezolid was calculated. Results are illustrated in
Figure 7.
The tests for determining the stability of line-
zolid in human serum and water demonstrated that
the linezolid samples are stable for at least three
freeze-thaw cycles. After three cycles of freeze-thaw,
the concentration of linezolid in human serum was
90.7 ± 0.58% and in water was 92.8 ± 0.29% of the
mean concentration of the fresh prepared samples.
Application to pharmacokinetic studies in
patients 
This analytical method was applied to quantify
serum linezolid concentration for clinical pharmaco-
kinetic studies. A complete steady-state patient
curve after administration of 600 mg ZivoxidÆ i.v.
every 12 h is shown Figure 8.
Figure 5. The HPLC/UV-HPLC/DAD correlation for 82 serum samples. The 95% confidence interval is shown 
Figure 6. Short-term and long-term stability of linezolid at 1.0, 7.5
and 15.0 µg/mL in human serum samples at room temperature
(A), at 4OC (B) storage for 24 h and at -30OC for 44 days (C)
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DISCUSSION
An analytical method for the rapid and precise
determination of linezolid in human serum using
protein precipitation and UV or DAD detection has
been developed.
During the validation of described method,
piperacillin was used as an internal standard. We
gave up using this internal standard similarly as
Swoboda et al. (18) because no significant differ-
ences in precision and accuracy during method val-
idation had been found. Furthemore, longer time of
analysis had been noted (15 min). We also did not
encounter any problems with retention time stability
or column lifetime. More than 1500 samples were
successfully analyzed on the same column. 
Figure 7. Tests confirmed the stability of linezolid in human serum and in water during three freezeñthaw cycles. The linezolid levels in
serum were measured by HPLC/UV and by HPLC/DAD
Figure 8. Serum linezolid concentration versus time profile at steady state in critically ill patient after its administration of a 600 mg infu-
sion every 12 h
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The advantage of our method over those previ-
ously published lies in the simple preparation of the
samples. We evaluated the use of acetonitrile,
methanol and 10% perchloric acid for protein pre-
cipitation. The best recoveries were obtained using
methanol (data not shown). Compared to other pro-
cedures reported in the literature, our method is cost-
effective (12, 13, 19). The relatively low price of a
single column and reagents are important for phar-
macokinetic and clinical laboratory investigations. 
In the presented analytical method we used
only 200 µL of serum samples. Small volume of
sample is very important for pharmacokinetic stud-
ies, particularly in critically ill patients and children.
We were able to develop a rapid HPLC assay with a
total run time < 10 min. The retention times of line-
zolid in serum/plasma described by other authors
were 10 and 20 min (10, 13, 25). 
The blank serum showed no interference of
endogenous substances in the analysis of linezolid.
Potentially co-administered drugs had different
retention times, compared to linezolid or were not
extracted and detected. Calibration range was
based on human serum linezolid concentrations
during the pharmacokinetic steady-state when line-
zolid was administered at 600 mg twice daily intra-
venously. The calibration ranges reported in previ-
ously described linezolid assays for plasma sam-
ples extend only to 20.0 µg/mL (15, 17, 25). In
contrast, the calibration range from 0.50 to 30.0
µg/mL used in this assay is more applicable for use
in a clinical setting, because such high linezolid
concentrations have been reported (27, 28). The
complete recovery of linezolid from the serum
(approximately 100%) reported for this current
method provides evidence that this simple extrac-
tion procedure is satisfactory. Acceptable varia-
tions in intra-day precision and accuracy testing
were observed for both method (HPLC/UV and
DAD). Statistical analysis of the results obtained
Table 2. Intra-day accuracy and precision from the determination of linezolid in human serum by HPLC-UV






CV Relative error (RE)
[µg/mL] [%] [%]
0.5  0.56 ± 0.03 4.69 12.63
2.5  2.67 ± 0.10 3.59 6.65  
5.0  5.12 ± 0.13 2.63 2.40  
10.0  9.70 ± 0.35 3.56 3.04  
20.0  19.66 ± 0.51 2.60 1.68  
30.0  30.29 ± 1.05 3.47 0.97
Table 3. Intra-day accuracy and precision from the determination of linezolid in human serum by HPLC-






CV Relative error (RE)
[µg/mL] [%] [%]
0.5  0.55 ± 0.03 5.42 10.85
2.5  2.58 ± 0.04 1.74 3.18
5.0  5.06 ± 0.03 0.67 1.11
10.0  9.89 ± 0.08 0.76 1.06
20.0  19.69 ± 0.18 0.92 1.53
30.0  30.22 ± 0.29 0.97 0.74
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using Student's t-test revealed no significant differ-
ence between the performance of the two methods
regarding the accuracy and precision. This method
showed a LOQ of 0.25 µg/mL for HPLC/UV and
0.5 µg/mL for HPLC/DAD method and required
only 200 µL serum samples. Other published meth-
ods using protein precipitation showed LOQs sim-
ilar to our method (0.25-1.0 µg/mL), but required
much higher volume of plasma (up to 500  µL).
LOQs were sufficient for clinical applications, as
reported minimal concentrations were higher than
0.5 µg/mL at recommended dosages (27, 28).
Moreover, according to the European Committee
on Antimicrobial Susceptibility Testing, clinical
breakpoints of linezolid (ranging from 0.5 to 4.0
µg/mL) are greater than our LOQ, allowing clinical
applications of this method (29).
Under investigated conditions, no degradation
of tested compound was observed. Linezolid con-
centrations remained stable after three freeze-thaw
cycles of serum samples, storage on the bench top at
room temperature for up to 24 h and over 6 weeks at
ñ30OC. Extracts were also stable in the autosampler
for 24 h. These results are consistent with previous
reports (12, 13, 15, 17-19, 25). 
The method was used for one critically ill
patient for therapeutic drug monitoring, and individ-
ual dosage regimen of linezolid. Linezolid serum
concentration monitored in patient was 23 µg/mL at
the 1st h (15-30.0 µg/mL, reference) and through
concentrations of 3.8 µg /mL at 12th h (3.0-10.0
µg/mL, reference). Obtained results indicate that
HPLC/UV and DAD analyses yield reliable results
for monitoring linezolid levels in blood samples.
This assay shares the favorable attributes of being
simple and rapid compared to two previously report-
ed assays. Moreover, short retention time (9.0 min)
is appropriate and convenient for analysis of clinical
samples. 
CONCLUSION
In this report, we describe an assay we devel-
oped for measuring the concentration of linezolid in
low-volume serum samples. This method appears to
be suitable for use in the clinical laboratory for drug
monitoring and pharmacokinetic studies. Our
method can be routinely performed in clinical diag-
nostic laboratories using a basic HPLC/UV or DAD
system. The method is simple, reliable, and repro-
ducible. The lower limits of quantification allow the
measurement of linezolid concentrations in plasma
and tissue down to the minimal inhibitory concen-
tration values reported for most relevant Gram-pos-
itive pathogens, including MRSA (methicillin-
resistant Staphylococcus aureus) and VRE (van-
comycin-resistant Enterococcus) (29). In summary,
proposed methods can be used for the determination
of linezolid in human serum in laboratory as well as
in clinical applications.
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